Cellectis Nine-Month Net Loss Widens to $101.1 Million in 2026
According to TradingView, Cellectis reported a $101.1M nine-month loss and expects its cash to fund operations into the second half of 2028.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
According to TradingView, Cellectis reported a net loss of $101.1 million for the nine months ended September 30, 2026, compared with $41.3 million a year earlier. Cash and deposits stood at $149 million at period end, down $62 million from December 31, 2025. Revenue and other income fell to $19.9 million from $67.4 million, mainly because of lower activity under the AstraZeneca research plans.
The company expects funding into the second half of 2028 once its realignment is fully implemented. A headcount reduction of up to 70% is planned, subject to consultation with the French works council. Clinical data from the HEAL-101 trial is expected in the second half of 2027.
why it matters
The company is shifting from cell therapy toward in vivo gene editing, so investors will watch cost cuts, the pace of cash burn and early clinical results. For shareholders, the key question is whether the restructuring can meaningfully slow the rate of losses.
market impact
Cellectis shares (ALCLS): widening losses and shrinking cash weigh on the stock
tags
instruments
sources
- Cellectis (ALCLS) Reports $101.1M Nine-Month Net Loss; Cash Runway Into H2 2028 — TradingView, 13 November 2026 at 00:24 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗